Anguilla

Reimbursed Care Access

Anguilla (a British Overseas Territory) maintains strict controls on most classical psychedelics under its criminal/drug-control framework and through regional enforcement practice; there is no publicly documented, reimbursed medical psychedelic program on the island. Ketamine is used in routine clinical practice internationally as an anaesthetic (and is on the WHO essential medicines list), but there is no evidence of an esketamine (Spravato) approval, public reimbursement program, or established psychedelic-assisted therapy roll‑out in Anguilla; possession or supply of most tryptamines, phenethylamines and related compounds is treated as an illegal controlled‑drugs matter under local criminal law enforcement practices. [https://docstore.ohchr.org/SelfServices/FilesHandler.ashx?enc=bg9yZTlzMUeKmk8REiLml2t2zfabMRT8OoZws4lNgdOKbBAIi4z1TTcvon8dqcHZUSbzfgBAEVExB9u5WzP8sJyU0BYQQd0xpS69Wl5AHYs%3D|UK report on Overseas Territories (includes Anguilla)] [https://www.who.int/groups/expert-committee-on-selection-and-use-of-essential-medicines/essential-medicines-lists|WHO Model List of Essential Medicines (ketamine entry)]